Prot #BGB-11417-301: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB�11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusActive
Effective start/end date5/31/245/31/27

Funding

  • BeiGene USA, Inc. (Prot #BGB-11417-301)